<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">oncotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский онкологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian journal of oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1814-4861</issn><issn pub-type="epub">2312-3168</issn><publisher><publisher-name>Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21294/1814-4861-2024-23-5-93-102</article-id><article-id custom-type="elpub" pub-id-type="custom">oncotomsk-3272</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОПЫТ РАБОТЫ ОНКОЛОГИЧЕСКИХ УЧРЕЖДЕНИЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ONCOLOGY PRACTICE</subject></subj-group></article-categories><title-group><article-title>Анализ результатов хирургического лечения рака почки с опухолевым тромбозом нижней полой вены: опыт одного центра</article-title><trans-title-group xml:lang="en"><trans-title>Analysis of surgical treatment outcomes for renal cell carcinoma with inferior vena cava tumor thrombosis: a single-center experience</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0223-0753</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гамаюнов</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gamayunov</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гамаюнов Сергей Викторович, доктор медицинских наук, главный врач, 603163, г. Нижний Новгород, ул. Деловая, 11/1;</p><p>профессор кафедры онкологии, лучевой терапии и лучевой диагностики им. проф. Н.Е. Яхонтова, 603950, г. Нижний Новгород, пл. Минина и Пожарского, 10/1</p></bio><bio xml:lang="en"><p>Sergey V. Gamayunov, MD, DSc, Chief Physician, 11/1, Delovaya St., Nizhny Novgorod, 603163;</p><p>Professor, Prof. N.E. Yakhontov Department of Oncology, Radiation Therapy and Diagnostic Imaging, 10/1, Minin and Pozharsky Sq., Nizhny Novgorod, 603950</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3313-0285</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ашимов</surname><given-names>Э. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ashimov</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ашимов Эркин Абдиманапович, онколог-хирург 2-го онкологического отделения абдоминальной онкологии и рентгенхирургических методов диагностики и лечения, 603163, г. Нижний Новгород, ул. Деловая, 11/1;</p><p>ассистент кафедры факультетской хирургии и трансплантологии, 603950, г. Нижний Новгород, пл. Минина и Пожарского, 10/1</p></bio><bio xml:lang="en"><p>Erkin A. Ashimov, MD, Oncologist, 2nd Oncology Department of Abdominal Oncology and Radiosurgical Methods of Diagnosis and Treatment, 11/1, Delovaya St., Nizhny Novgorod, 603163;</p><p>Assistant, Department of Faculty Surgery and Transplantology, 10/1, Minin and Pozharsky Sq., Nizhny Novgorod, 603950</p></bio><email xlink:type="simple">ashimov-erkin@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9202-1321</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Киселев</surname><given-names>Н. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Kiselev</surname><given-names>N. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Киселев Николай Михайлович, кандидат медицинских наук, доцент кафедры факультетской хирургии и трансплантологии, 603163, г. Нижний Новгород, ул. Деловая, 11/1</p><p>заведующий 2-м онкологическим отделением абдоминальной онкологии и рентгенхирургических методов диагностики и лечения, 603950, г. Нижний Новгород, пл. Минина и Пожарского, 10/1</p></bio><bio xml:lang="en"><p>Nikolay M. Kiselev, MD, PhD, Associate Professor, Department of Faculty Surgery and Transplantology, 10/1, Minin and Pozharsky Sq., Nizhny Novgorod, 603950;</p><p>Head of the 2nd Oncology Department of Abdominal Oncology and Radiosurgical Methods of Diagnosis and Treatment, 11/1, Delovaya St., Nizhny Novgorod, 603163</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каров</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Karov</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Каров Владимир Александрович, заведующий 12-м онкологическим отделением онкоурологии, </p><p>603163, г. Нижний Новгород, ул. Деловая, 11/1</p></bio><bio xml:lang="en"><p>Vladimir A. Karov, MD, Head of the 12th Oncology Department of Oncourology, </p><p>11/1, Delovaya St., Nizhny Novgorod, 603163</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Спиридонов</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Spiridonov</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Спиридонов Михаил Александрович, онколог-хирург 12-го онкологического отделения онкоурологии,</p><p>603163, г. Нижний Новгород, ул. Деловая, 11/1</p></bio><bio xml:lang="en"><p>Mikhail A. Spiridonov, MD, Oncologist, 12th Oncology Department of Oncourology, </p><p>11/1, Delovaya St., Nizhny Novgorod, 603163</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Заречнова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zarechnova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Заречнова Наталья Владимировна, кандидат медицинских наук, ассистент кафедры анестезиологии, реаниматологии и трансфузиологии, 603163, г. Нижний Новгород, ул. Деловая, 11/1;</p><p>заместитель главного врача по медицинской части, руководитель центра  анестезиологии-реанимации, 603950, г. Нижний Новгород, пл. Минина и Пожарского, 10/1</p></bio><bio xml:lang="en"><p>Natalia V. Zarechnova, MD, PhD, Assistant, Department of Anesthesiology, Intensive Care and Transfusiology, 10/1, Minin and Pozharsky Sq., Nizhny Novgorod, 603950;</p><p>Deputy Chief Medical Officer, Head of the Center for Anesthesiology and Intensive Care, 11/1, Delovaya St., Nizhny Novgorod, 603163</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Загайнов</surname><given-names>В. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Zagainov</surname><given-names>V. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Загайнов Владимир Евгеньевич, доктор медицинских наук, профессор, заведующий кафедрой факультетской хирургии и трансплантологии, директор института хирургии и онкологии, диспансер» Минздрава России, 603163, г. Нижний Новгород, ул. Деловая, 11/1;</p><p>заместитель главного врача по науке и инновациям, 603950, г. Нижний Новгород, пл. Минина и Пожарского, 10/1</p></bio><bio xml:lang="en"><p>Vladimir E. Zagainov, MD, DSc, Professor, Head of Department of Faculty Surgery and Transplantology, Director of the Institute of Surgery and Oncology, 10/1, Minin and Pozharsky Sq., Nizhny Novgorod, 603950;</p><p>Deputy Chief Physician for Science and Innovation, 11/1, Delovaya St., Nizhny Novgorod, 603163</p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ГАУЗ НО НИИКО «Нижегородский областной клинический онкологический диспансер» Минздрава России;&#13;
ФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава России<country>Россия</country></aff><aff xml:lang="en">Nizhny Novgorod Regional Clinical Cancer Center of the Ministry of Health of the Russia;&#13;
Privolzhsky Research Medical University of the Ministry of Health of the Russia<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ГАУЗ НО НИИКО «Нижегородский областной клинический онкологический диспансер» Минздрава России;&#13;
ФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава России<country>Россия</country></aff><aff xml:lang="en">Privolzhsky Research Medical University of the Ministry of Health of the Russia;&#13;
Nizhny Novgorod Regional Clinical Cancer Center of the Ministry of Health of the Russia<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">ГАУЗ НО НИИКО «Нижегородский областной клинический онкологический диспансер» Минздрава России<country>Россия</country></aff><aff xml:lang="en">Nizhny Novgorod Regional Clinical Cancer Center of the Ministry of Health of the Russia<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru">ГАУЗ НО НИИКО «Нижегородский областной клинический онкологический;&#13;
ФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава России<country>Россия</country></aff><aff xml:lang="en">Privolzhsky Research Medical University of the Ministry of Health of the Russia;&#13;
Nizhny Novgorod Regional Clinical Cancer Center of the Ministry of Health of the Russia<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>10</day><month>11</month><year>2024</year></pub-date><volume>23</volume><issue>5</issue><fpage>93</fpage><lpage>102</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гамаюнов С.В., Ашимов Э.А., Киселев Н.М., Каров В.А., Спиридонов М.А., Заречнова Н.В., Загайнов В.Е., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Гамаюнов С.В., Ашимов Э.А., Киселев Н.М., Каров В.А., Спиридонов М.А., Заречнова Н.В., Загайнов В.Е.</copyright-holder><copyright-holder xml:lang="en">Gamayunov S.V., Ashimov E.A., Kiselev N.M., Karov V.A., Spiridonov M.A., Zarechnova N.V., Zagainov V.E.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.siboncoj.ru/jour/article/view/3272">https://www.siboncoj.ru/jour/article/view/3272</self-uri><abstract><p>Цель исследования – анализ непосредственных результатов хирургического лечения рака почки (РП) с опухолевым тромбозом нижней полой вены (ОТНПВ) на базе одного онкологического центра.</p><sec><title>Материал и методы</title><p>Материал и методы. Ретроспективный анализ данных 25 пациентов, получивших хирургическое лечение по поводу локального и распространенного РП с ОТНПВ с 01.2021 по 12.2022 г. Медиана наблюдения за пациентами составила 21 мес (ДИ 95 % 14,3–33 мес). Больные распределены на группы согласно классификации Mayo по ОТНПВ: I тип – 8, II тип – 8, III тип – 9 пациентов.</p></sec><sec><title>Результаты</title><p>Результаты. Резекция НПВ: тангенциальная выполнена 20 (80 %), циркулярная – 3 (12 %), экстирпация НПВ – 2 (8 %) пациентам. Медиана интраоперационной кровопотери – 600 мл (от 250 до 1700 мл). Частота послеоперационных осложнений – 28 %, распределение по классам Clavien–Dindo: III – 4, IV – 2, V – 1, выявлено увеличение частоты осложнений III–IV класса у пациентов с Mayo III, однако значимых различий не отмечено (p=0,153). Наиболее частым осложнением было острое повреждение почек. Двум (8 %) пациентам потребовалось повторное хирургическое вмешательство. Один пациент умер по причине сепсиса. Значимые различия получены при оценке показателей кровопотери (p=0,003), количества гемотрансфузий эритроцитарной взвеси (p=0,006), времени оперативного вмешательства (p=0,014), и они превалировали в группе с уровнем тромба Mayo III. Однако медиана продолжительности пребывания в стационаре не отличалась в подгруппах (p=0,978) и составила 6 койко-дней – в диапазоне от 4 до 20 дней в общей группе. Тридцатидневная послеоперационная летальность составила 4 %.</p></sec><sec><title>Заключение</title><p>Заключение. Наш опыт показывает, что хирургическое лечение рака почки с опухолевым тромбом нижней полой вены осуществимо и обеспечивает приемлемые хирургические и онкологические результаты. Однако частота осложнений и послеоперационная летальность выше у пациентов с уровнем тромба Mayo III, что требует тщательной селекции больных.</p></sec></abstract><trans-abstract xml:lang="en"><p>The purpose of the study was to analyze surgical treatment outcomes for renal cell carcinoma (RCC) with inferior vena cava tumor thrombosis (IVC-TT) on the basis of one cancer center.</p><sec><title>Material and Methods</title><p>Material and Methods. A retrospective analysis of treatment outcomes of 25 patients with locally advanced and metastatic RCC with IVC-TT, who underwent surgery from 01.2021 to 12.2022, was carried out. The median follow-up was 21 months (95 % CI 14.3–33 months). The patients were divided into groups according to the Mayo IVC-TT classifcation: Type I: 8 patients, type II: 8 patients, and type III: 9 patients.</p></sec><sec><title>Results</title><p>Results. Tangential IVC resection was done in 20 (80 %) cases, circular-in 3 (12 %) cases, and IVC extirpation was done in 2 (8 %) cases. The median intraoperative blood loss was 600 ml (from 250 to 1700 ml). The incidence of postoperative complications was 28 %, distribution by Clavien–Dindo classes was: III – 4, IV – 2, V – 1, an increase in the incidence of complications of class III–IV was revealed in patients with Mayo type III, however, no statistically signifcant differences were found (p=0.153). The most common complication was acute kidney injury. Two (8 %) patients required repeated surgical intervention. One patient died due to sepsis. Statistically signifcant differences were obtained in blood loss (p=0.003), the number of erythrocyte suspension blood transfusions (p=0.006), and the time of surgery (p=0.014) and prevailed in the group with the Mayo III level. However, the median length of hospital stay did not differ in the subgroups (p=0.978) and amounted to 6 bed days in the range from 4 to 20 days in the general group. The 30-day postoperative mortality rate was 4 %.</p></sec><sec><title>Conclusion</title><p>Conclusion. Our experience has shown that surgical treatment of RCC with IVC-TT is feasible and provides acceptable surgical and oncological outcomes. However, the complication rate and postoperative mortality are higher in patients with Mayo III thrombus levels, requiring careful patient selection.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рак почки</kwd><kwd>тромбоз нижней полой вены</kwd><kwd>резекция нижней полой вены</kwd><kwd>хирургическое лечение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>renal cell carcinoma</kwd><kwd>thrombosis of the inferior vena cava</kwd><kwd>resection of the inferior vena cava</kwd><kwd>surgical treatment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–49. doi: 10.3322/caac.21660.</mixed-citation><mixed-citation xml:lang="en">Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–49. doi: 10.3322/caac.21660.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Padala S.A., Barsouk A., Thandra K.C., Saginala K., Mohammed A., Vakiti A., Rawla P., Barsouk A. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020; 11(3): 79–87. doi: 10.14740/wjon1279.</mixed-citation><mixed-citation xml:lang="en">Padala S.A., Barsouk A., Thandra K.C., Saginala K., Mohammed A., Vakiti A., Rawla P., Barsouk A. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020; 11(3): 79–87. doi: 10.14740/wjon1279.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Tohi Y., Makita N., Suzuki I., Suzuki R., Kubota M., Sugino Y., Inoue K., Kawakita M. En bloc laparoscopic radical nephrectomy with inferior vena cava thrombectomy: A single-institution experi- ence. Int J Urol. 2019; 26(3): 363–8. doi: 10.1111/iju.13873.</mixed-citation><mixed-citation xml:lang="en">Tohi Y., Makita N., Suzuki I., Suzuki R., Kubota M., Sugino Y., Inoue K., Kawakita M. En bloc laparoscopic radical nephrectomy with inferior vena cava thrombectomy: A single-institution experi- ence. Int J Urol. 2019; 26(3): 363–8. doi: 10.1111/iju.13873.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Powles T., Albiges L., Bex A., Grünwald V., Porta C., Procopio G., Schmidinger M., Suárez C., de Velasco G.; ESMO Guidelines Committee. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021; 32(12): 1511–9. doi: 10.1016/j.annonc.2021.09.014.</mixed-citation><mixed-citation xml:lang="en">Powles T., Albiges L., Bex A., Grünwald V., Porta C., Procopio G., Schmidinger M., Suárez C., de Velasco G.; ESMO Guidelines Committee. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021; 32(12): 1511–9. doi: 10.1016/j.annonc.2021.09.014.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Motzer R.J., Jonasch E., Agarwal N., Alva A., Baine M., Beckermann K., Carlo M.I., Choueiri T.K., Costello B.A., Derweesh I.H., Desai A., Ged Y., George S., Gore J.L., Haas N., Hancock S.L., Kapur P., Kyriakopoulos C., Lam E.T., Lara P.N., Lau C., Lewis B., Madoff D.C., Manley B., Michaelson M.D., Mor- tazavi A., Nandagopal L., Plimack E.R., Ponsky L., Ramalingam S., Shuch B., Smith Z.L., Sosman J., Dwyer M.A., Gurski L.A., Motter A. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(1): 71–90. doi: 10.6004/jnccn.2022.0001.</mixed-citation><mixed-citation xml:lang="en">Motzer R.J., Jonasch E., Agarwal N., Alva A., Baine M., Beckermann K., Carlo M.I., Choueiri T.K., Costello B.A., Derweesh I.H., Desai A., Ged Y., George S., Gore J.L., Haas N., Hancock S.L., Kapur P., Kyriakopoulos C., Lam E.T., Lara P.N., Lau C., Lewis B., Madoff D.C., Manley B., Michaelson M.D., Mor- tazavi A., Nandagopal L., Plimack E.R., Ponsky L., Ramalingam S., Shuch B., Smith Z.L., Sosman J., Dwyer M.A., Gurski L.A., Motter A. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(1): 71–90. doi: 10.6004/jnccn.2022.0001.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Singer E.A., Rumble R.B., van Veldhuizen P.J. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline Q&amp;A. JCO Oncol Pract. 2023; 19(3): 127–31. doi: 10.1200/OP.22.00660.</mixed-citation><mixed-citation xml:lang="en">Singer E.A., Rumble R.B., van Veldhuizen P.J. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline Q&amp;A. JCO Oncol Pract. 2023; 19(3): 127–31. doi: 10.1200/OP.22.00660.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mason N.T., Joshi V.B., Adashek J.J., Kim Y., Shah S.S., Schneider A.M., Chadha J., Jim H.S.L., Byrne M.M., Gilbert S.M., Manley B.J., Spiess P.E., Chahoud J. Cost Efectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma. Eur Urol Oncol. 2023; 6(3): 331–8. doi: 10.1016/j.euo.2023.01.011.</mixed-citation><mixed-citation xml:lang="en">Mason N.T., Joshi V.B., Adashek J.J., Kim Y., Shah S.S., Schneider A.M., Chadha J., Jim H.S.L., Byrne M.M., Gilbert S.M., Manley B.J., Spiess P.E., Chahoud J. Cost Efectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma. Eur Urol Oncol. 2023; 6(3): 331–8. doi: 10.1016/j.euo.2023.01.011.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wang B.S., Li Y.Z., Fang Y.Y., Zhang S.D., Ma L.L. Imaging predictors for assessment of inferior vena cava wall invasion in patients with renal cell carcinoma and inferior vena cava tumor thrombus: a retrospective study. Chin Med J (Engl). 2020; 133(17): 2078–83. doi: 10.1097/CM9.0000000000000828.</mixed-citation><mixed-citation xml:lang="en">Wang B.S., Li Y.Z., Fang Y.Y., Zhang S.D., Ma L.L. Imaging predictors for assessment of inferior vena cava wall invasion in patients with renal cell carcinoma and inferior vena cava tumor thrombus: a retrospective study. Chin Med J (Engl). 2020; 133(17): 2078–83. doi: 10.1097/CM9.0000000000000828.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Z., Li L., Hong P., Zhu G., Tang S., Zhao X., Zhang Q., Wang G., He W., Zhang H., Xue H., Cui L., Ge H., Jiang J., Zhang S., Cao F., Yan J., Ma F., Liu C., Ma L., Wang S. A Predictive Model for Tumor Invasion of the Inferior Vena Cava Wall Using Multimodal Imaging in Patients with Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus. Biomed Res Int. 2020. doi: 10.1155/2020/9530618.</mixed-citation><mixed-citation xml:lang="en">Liu Z., Li L., Hong P., Zhu G., Tang S., Zhao X., Zhang Q., Wang G., He W., Zhang H., Xue H., Cui L., Ge H., Jiang J., Zhang S., Cao F., Yan J., Ma F., Liu C., Ma L., Wang S. A Predictive Model for Tumor Invasion of the Inferior Vena Cava Wall Using Multimodal Imaging in Patients with Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus. Biomed Res Int. 2020. doi: 10.1155/2020/9530618.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Yuan S.M. Surgical treatment of renal cell carcinoma with inferior vena cava tumor thrombus. Surg Today. 2022; 52(8): 1125–33. doi: 10.1007/s00595-021-02429-9.</mixed-citation><mixed-citation xml:lang="en">Yuan S.M. Surgical treatment of renal cell carcinoma with inferior vena cava tumor thrombus. Surg Today. 2022; 52(8): 1125–33. doi: 10.1007/s00595-021-02429-9.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Garg H., Psutka S.P., Hakimi A.A., Kim H.L., Mansour A.M., Pruthi D.K., Liss M.A., Wang H., Gaspard C.S., Ramamurthy C., Svatek R.S., Kaushik D. A Decade of Robotic-Assisted Radical Nephrectomy with Inferior Vena Cava Thrombectomy: A System- atic Review and Meta-Analysis of Perioperative Outcomes. J Urol. 2022; 208(3): 542–60. doi: 10.1097/JU.0000000000002829.</mixed-citation><mixed-citation xml:lang="en">Garg H., Psutka S.P., Hakimi A.A., Kim H.L., Mansour A.M., Pruthi D.K., Liss M.A., Wang H., Gaspard C.S., Ramamurthy C., Svatek R.S., Kaushik D. A Decade of Robotic-Assisted Radical Nephrectomy with Inferior Vena Cava Thrombectomy: A System- atic Review and Meta-Analysis of Perioperative Outcomes. J Urol. 2022; 208(3): 542–60. doi: 10.1097/JU.0000000000002829.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tabbara M.M., Ciancio G. Surgical treatment of renal cell carcinoma with inferior vena cava tumor thrombus. Surg Today. 2023; 53(7): 855–6. doi: 10.1007/s00595-022-02514-7.</mixed-citation><mixed-citation xml:lang="en">Tabbara M.M., Ciancio G. Surgical treatment of renal cell carcinoma with inferior vena cava tumor thrombus. Surg Today. 2023; 53(7): 855–6. doi: 10.1007/s00595-022-02514-7.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Berczi A., Flasko T., Szerafn T., Thomas B., Bacso Z., Berczi C. Surgical Management and Outcome of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus. Urol Int. 2017; 99(3): 267–71. doi: 10.1159/000464108.</mixed-citation><mixed-citation xml:lang="en">Berczi A., Flasko T., Szerafn T., Thomas B., Bacso Z., Berczi C. Surgical Management and Outcome of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus. Urol Int. 2017; 99(3): 267–71. doi: 10.1159/000464108.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Z., Zhang Q., Zhao X., Zhu G., Tang S., Hong P., Ge L., Zhang S., Wang G., Tian X., Zhang H., Liu C., Ma L. Inferior vena cava interruption in renal cell carcinoma with tumor thrombus: surgical strategy and perioperative results. BMC Surg. 2021; 21(1): 402. doi: 10.1186/s12893-021-01400-2.</mixed-citation><mixed-citation xml:lang="en">Liu Z., Zhang Q., Zhao X., Zhu G., Tang S., Hong P., Ge L., Zhang S., Wang G., Tian X., Zhang H., Liu C., Ma L. Inferior vena cava interruption in renal cell carcinoma with tumor thrombus: surgical strategy and perioperative results. BMC Surg. 2021; 21(1): 402. doi: 10.1186/s12893-021-01400-2.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Blute M.L., Leibovich B.C., Lohse C.M., Cheville J.C., Zincke H. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int. 2004; 94(1): 33–41. doi: 10.1111/j.1464-410X.2004.04897.x.</mixed-citation><mixed-citation xml:lang="en">Blute M.L., Leibovich B.C., Lohse C.M., Cheville J.C., Zincke H. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int. 2004; 94(1): 33–41. doi: 10.1111/j.1464-410X.2004.04897.x.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kandori S., Kojima T., Nishiyama H. The updated points of TNM classifcation of urological cancers in the 8th edition of AJCC and UICC. Jpn J Clin Oncol. 2019; 49(5): 421–25. doi: 10.1093/jjco/hyz017.</mixed-citation><mixed-citation xml:lang="en">Kandori S., Kojima T., Nishiyama H. The updated points of TNM classifcation of urological cancers in the 8th edition of AJCC and UICC. Jpn J Clin Oncol. 2019; 49(5): 421–25. doi: 10.1093/jjco/hyz017.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Aldin A., Besiroglu B., Adams A., Monsef I., Piechotta V., Tomlinson E., Hornbach C., Dressen N., Goldkuhle M., Maisch P., Dahm P., Heidenreich A., Skoetz N. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023; 5(5). doi: 10.1002/14651858.CD013798.pub2.</mixed-citation><mixed-citation xml:lang="en">Aldin A., Besiroglu B., Adams A., Monsef I., Piechotta V., Tomlinson E., Hornbach C., Dressen N., Goldkuhle M., Maisch P., Dahm P., Heidenreich A., Skoetz N. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023; 5(5). doi: 10.1002/14651858.CD013798.pub2.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Berg A.A. Malignant hypernephroma of the kidney, its clinical course and diagnosis, with a description of the author’s method of radical operative cure. Surg Gynecol Obstet. 1913; 17: 463–71.</mixed-citation><mixed-citation xml:lang="en">Berg A.A. Malignant hypernephroma of the kidney, its clinical course and diagnosis, with a description of the author’s method of radical operative cure. Surg Gynecol Obstet. 1913; 17: 463–71.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Martínez-Salamanca J.I., Linares E., González J., Bertini R., Carballido J.A., Chromecki T., Ciancio G., Daneshmand S., Evans C.P., Gontero P., Haferkamp A., Hohenfellner M., Huang W.C., Koppie T.M., Master V.A., Matloob R., McKiernan J.M., Mlynarczyk C.M., Montorsi F., Nguyen H.G., Novara G., Pahernik S., Palou J., Pruthi R.S., Ramaswamy K., Faba O.R., Russo P., Shariat S.F., Spahn M., Terrone C., Tilki D., Vergho D., Wallen E.M., Xylinas E., Zigeuner R., Libertino J.A. Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Curr Urol Rep. 2014; 15(5): 404. doi: 10.1007/s11934-014-0404-7.</mixed-citation><mixed-citation xml:lang="en">Martínez-Salamanca J.I., Linares E., González J., Bertini R., Carballido J.A., Chromecki T., Ciancio G., Daneshmand S., Evans C.P., Gontero P., Haferkamp A., Hohenfellner M., Huang W.C., Koppie T.M., Master V.A., Matloob R., McKiernan J.M., Mlynarczyk C.M., Montorsi F., Nguyen H.G., Novara G., Pahernik S., Palou J., Pruthi R.S., Ramaswamy K., Faba O.R., Russo P., Shariat S.F., Spahn M., Terrone C., Tilki D., Vergho D., Wallen E.M., Xylinas E., Zigeuner R., Libertino J.A. Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Curr Urol Rep. 2014; 15(5): 404. doi: 10.1007/s11934-014-0404-7.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Haidar G.M., Hicks T.D., El-Sayed H.F., Davies M.G. Treatment options and outcomes for caval thrombectomy and resection for renal cell carcinoma. J Vasc Surg Venous Lymphat Disord. 2017; 5(3): 430–6. doi: 10.1016/j.jvsv.2016.12.011.</mixed-citation><mixed-citation xml:lang="en">Haidar G.M., Hicks T.D., El-Sayed H.F., Davies M.G. Treatment options and outcomes for caval thrombectomy and resection for renal cell carcinoma. J Vasc Surg Venous Lymphat Disord. 2017; 5(3): 430–6. doi: 10.1016/j.jvsv.2016.12.011.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Horynecka Z., Jabłońska B., Kurek A., Lekstan A., Piaszczyński M., Mrowiec S., Oczkowicz G., Król R. Analysis of surgical outcomes in 102 patients with renal cell carcinoma with venous tumor thrombus: A retrospective observational singlecenter study. Medicine (Baltimore). 2022; 101(40). doi: 10.1097/MD.0000000000030808.</mixed-citation><mixed-citation xml:lang="en">Horynecka Z., Jabłońska B., Kurek A., Lekstan A., Piaszczyński M., Mrowiec S., Oczkowicz G., Król R. Analysis of surgical outcomes in 102 patients with renal cell carcinoma with venous tumor thrombus: A retrospective observational singlecenter study. Medicine (Baltimore). 2022; 101(40). doi: 10.1097/MD.0000000000030808.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Rehman Z.U., Ather M.H., Aziz W. Surgical Interventions for Renal Cell Carcinoma with Thrombus Extending into the Inferior Vena Cava: A Multidisciplinary Approach. Ann Vasc Dis. 2019; 12(1): 55–59. doi: 10.3400/avd.oa.18-00150.</mixed-citation><mixed-citation xml:lang="en">Rehman Z.U., Ather M.H., Aziz W. Surgical Interventions for Renal Cell Carcinoma with Thrombus Extending into the Inferior Vena Cava: A Multidisciplinary Approach. Ann Vasc Dis. 2019; 12(1): 55–59. doi: 10.3400/avd.oa.18-00150.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Agochukwu N., Shuch B. Clinical management of renal cell carcinoma with venous tumor thrombus. World J Urol. 2014; 32(3): 581–9. doi: 10.1007/s00345-014-1276-7.</mixed-citation><mixed-citation xml:lang="en">Agochukwu N., Shuch B. Clinical management of renal cell carcinoma with venous tumor thrombus. World J Urol. 2014; 32(3): 581–9. doi: 10.1007/s00345-014-1276-7.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Rooseno G., Hakim L., Djojodimedjo T. A systematic review and meta-analysis on the efcacy of preoperative renal artery embolization prior to radical nephrectomy for renal cell carcinoma: Is it necessary? Arch Ital Urol Androl. 2023; 95(4). doi: 10.4081/aiua.2023.12018.</mixed-citation><mixed-citation xml:lang="en">Rooseno G., Hakim L., Djojodimedjo T. A systematic review and meta-analysis on the efcacy of preoperative renal artery embolization prior to radical nephrectomy for renal cell carcinoma: Is it necessary? Arch Ital Urol Androl. 2023; 95(4). doi: 10.4081/aiua.2023.12018.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Subramanian V.S., Stephenson A.J., Goldfarb D.A., Fergany A.F., Novick A.C., Krishnamurthi V. Utility of preoperative renal artery embolization for management of renal tumors with inferior vena caval thrombi. Urology. 2009; 74(1): 154–9. doi: 10.1016/j.urology.2008.12.084.</mixed-citation><mixed-citation xml:lang="en">Subramanian V.S., Stephenson A.J., Goldfarb D.A., Fergany A.F., Novick A.C., Krishnamurthi V. Utility of preoperative renal artery embolization for management of renal tumors with inferior vena caval thrombi. Urology. 2009; 74(1): 154–9. doi: 10.1016/j.urology.2008.12.084.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Shanmugasundaram S., Cieslak J.A., Sare A., Chandra V., Shukla P.A., Kumar A. Preoperative embolization of renal cell carcinoma prior to partial nephrectomy: A systematic review and meta-analysis. Clin Imaging. 2021; 76: 205–12. doi: 10.1016/j.clinimag.2021.04.021.</mixed-citation><mixed-citation xml:lang="en">Shanmugasundaram S., Cieslak J.A., Sare A., Chandra V., Shukla P.A., Kumar A. Preoperative embolization of renal cell carcinoma prior to partial nephrectomy: A systematic review and meta-analysis. Clin Imaging. 2021; 76: 205–12. doi: 10.1016/j.clinimag.2021.04.021.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Tang G., Chen X., Wang J., He W., Niu Z. Adjuvant instant preoperative renal artery embolization facilitates the radical neph- rectomy and thrombectomy in locally advanced renal cancer with venous thrombus: a retrospective study of 54 cases. World J Surg Oncol. 2020; 18(1): 206. doi: 10.1186/s12957-020-01985-7.</mixed-citation><mixed-citation xml:lang="en">Tang G., Chen X., Wang J., He W., Niu Z. Adjuvant instant preoperative renal artery embolization facilitates the radical neph- rectomy and thrombectomy in locally advanced renal cancer with venous thrombus: a retrospective study of 54 cases. World J Surg Oncol. 2020; 18(1): 206. doi: 10.1186/s12957-020-01985-7.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Bex A., Mulders P., Jewett M., Wagstaff J., van Thienen J.V., Blank C.U., van Velthoven R., Del Pilar Laguna M., Wood L., van Melick H.H.E., Aarts M.J., Lattouf J.B., Powles T., de Jong I.J., Rottey S., Tombal B., Marreaud S., Collette S., Collette L., Haanen J. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol. 2019; 5(2): 164–70. doi: 10.1001/jamaoncol.2018.5543. Erratum in: JAMA Oncol. 2019; 5(2): 271. doi: 10.1001/jamaoncol.2019.0117.</mixed-citation><mixed-citation xml:lang="en">Bex A., Mulders P., Jewett M., Wagstaff J., van Thienen J.V., Blank C.U., van Velthoven R., Del Pilar Laguna M., Wood L., van Melick H.H.E., Aarts M.J., Lattouf J.B., Powles T., de Jong I.J., Rottey S., Tombal B., Marreaud S., Collette S., Collette L., Haanen J. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol. 2019; 5(2): 164–70. doi: 10.1001/jamaoncol.2018.5543. Erratum in: JAMA Oncol. 2019; 5(2): 271. doi: 10.1001/jamaoncol.2019.0117.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Tannir N.M., Albigès L., McDermott D.F., Burotto M., Choueiri T.K., Hammers H.J., Barthélémy P., Plimack E.R., Porta C., George S., Donskov F., Atkins M.B., Gurney H., Kollmannsberger C.K., Grimm M.O., Barrios C., Tomita Y., Castellano D., Grünwald V., Rini B.I., Jiang R., Desilva H., Fedorov V., Lee C.W., Motzer R.J. Nivolumab plus ipilimumab versus sunitinib for frst-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efcacy and safety from the phase III CheckMate 214 trial. Ann Oncol. 2024. doi: 10.1016/j.annonc.2024.07.727.</mixed-citation><mixed-citation xml:lang="en">Tannir N.M., Albigès L., McDermott D.F., Burotto M., Choueiri T.K., Hammers H.J., Barthélémy P., Plimack E.R., Porta C., George S., Donskov F., Atkins M.B., Gurney H., Kollmannsberger C.K., Grimm M.O., Barrios C., Tomita Y., Castellano D., Grünwald V., Rini B.I., Jiang R., Desilva H., Fedorov V., Lee C.W., Motzer R.J. Nivolumab plus ipilimumab versus sunitinib for frst-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efcacy and safety from the phase III CheckMate 214 trial. Ann Oncol. 2024. doi: 10.1016/j.annonc.2024.07.727.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Stewart G.D., Welsh S.J., Ursprung S., Gallagher F.A., Jones J.O., Shields J., Smith C.G., Mitchell T.J., Warren A.Y., Bex A., Boleti E., Carruthers J., Eisen T., Fife K., Hamid A., Laird A., Leung S., Malik J., Mendichovszky I.A., Mumtaz F., Oades G., Priest A.N., Riddick A.C.P., Venugopal B., Welsh M., Riddle K., Hopcroft L.E.M.; NAXIVA Trial Group; Jones R.J. A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). Br J Cancer. 2022; 127(6): 1051–60. doi: 10.1038/s41416-022-01883-7.</mixed-citation><mixed-citation xml:lang="en">Stewart G.D., Welsh S.J., Ursprung S., Gallagher F.A., Jones J.O., Shields J., Smith C.G., Mitchell T.J., Warren A.Y., Bex A., Boleti E., Carruthers J., Eisen T., Fife K., Hamid A., Laird A., Leung S., Malik J., Mendichovszky I.A., Mumtaz F., Oades G., Priest A.N., Riddick A.C.P., Venugopal B., Welsh M., Riddle K., Hopcroft L.E.M.; NAXIVA Trial Group; Jones R.J. A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). Br J Cancer. 2022; 127(6): 1051–60. doi: 10.1038/s41416-022-01883-7.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Abel E.J., Spiess P.E., Margulis V., Master V.A., Mann M., Zargar-Shoshtari K., Borregales L.D., Sexton W.J., Patil D., Matin S.F., Wood C.G., Karam J.A. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol. 2017; 198(2): 281–8. doi: 10.1016/j.juro.2017.03.011.</mixed-citation><mixed-citation xml:lang="en">Abel E.J., Spiess P.E., Margulis V., Master V.A., Mann M., Zargar-Shoshtari K., Borregales L.D., Sexton W.J., Patil D., Matin S.F., Wood C.G., Karam J.A. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol. 2017; 198(2): 281–8. doi: 10.1016/j.juro.2017.03.011.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Manso M., Pacheco-Figueiredo L., Santos-Silva A., Silva J., Silva C., Cruz F. Renal Cell Carcinoma with Venous Thrombus: Should Surgery Be Ofered When Metastasis Is Present at Diagno- sis? Urol Int. 2018; 101(4): 387–90. doi: 10.1159/000493510.</mixed-citation><mixed-citation xml:lang="en">Manso M., Pacheco-Figueiredo L., Santos-Silva A., Silva J., Silva C., Cruz F. Renal Cell Carcinoma with Venous Thrombus: Should Surgery Be Ofered When Metastasis Is Present at Diagno- sis? Urol Int. 2018; 101(4): 387–90. doi: 10.1159/000493510.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Kirkali Z., V. Poppel H. A critical analysis of surgery for kidney cancer with vena cava invasion. Eur Urol. 2007; 52(3): 658–62. doi: 10.1016/j.eururo.2007.05.009.</mixed-citation><mixed-citation xml:lang="en">Kirkali Z., V. Poppel H. A critical analysis of surgery for kidney cancer with vena cava invasion. Eur Urol. 2007; 52(3): 658–62. doi: 10.1016/j.eururo.2007.05.009.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
